| 25/08/22 | 07:05:00 | 25 Aug 2022 | | Tagrisso approved in Japan for early lung cancer |
| 25/08/22 | 07:00:03 | 25 Aug 2022 | | Lynparza approved in Japan for early breast cancer |
| 16/08/22 | 07:00:11 | 16 Aug 2022 | | Lynparza granted FDA priority review for PROpel |
| 15/08/22 | 07:00:06 | 15 Aug 2022 | | Enhertu improved PFS in mBC in DESTINY-Breast02 |
| 12/08/22 | 07:00:09 | 12 Aug 2022 | | Enhertu approved in US for HER2-mutant NSCLC |
| 11/08/22 | 07:00:12 | 11 Aug 2022 | | Acquisition of TeneoTwo completed |
| 08/08/22 | 07:10:05 | 8 Aug 2022 | | Enhertu approved in the US for HER2-low mBC |
| 04/08/22 | 07:00:07 | 4 Aug 2022 | | Lynparza approved in EU for early breast cancer |
| 01/08/22 | 17:00:02 | 1 Aug 2022 | | Director/PDMR Shareholding |
| 01/08/22 | 15:05:01 | 1 Aug 2022 | | Director/PDMR Shareholding |
| 01/08/22 | 15:00:01 | 1 Aug 2022 | | Total Voting Rights |
| 29/07/22 | 07:01:05 | 29 Jul 2022 | | Chair succession |
| 29/07/22 | 07:00:11 | 29 Jul 2022 | | Half-year Report |
| 25/07/22 | 07:10:05 | 25 Jul 2022 | | Tezspire recommended for EU approval in asthma |
| 25/07/22 | 07:05:06 | 25 Jul 2022 | | Ultomiris recommended for EU approval for gMG |
| 25/07/22 | 07:00:06 | 25 Jul 2022 | | Enhertu granted Priority Review for HER2-low mBC |
| 19/07/22 | 07:00:07 | 19 Jul 2022 | | Enhertu approved in EU for HER2-positive mBC |
| 05/07/22 | 07:00:04 | 5 Jul 2022 | | AstraZeneca to acquire TeneoTwo and T cell engager |
| 01/07/22 | 15:00:12 | 1 Jul 2022 | | Total Voting Rights |
| 30/06/22 | 07:00:08 | 30 Jun 2022 | | Imfinzi improved pCR in resectable lung cancer |
| 27/06/22 | 07:05:04 | 27 Jun 2022 | | Enhertu recommended for breast cancer EU approval |
| 27/06/22 | 07:00:08 | 27 Jun 2022 | | Lynparza recommended in EU for early breast cancer |
| 21/06/22 | 07:00:06 | 21 Jun 2022 | | Eplontersen Ph III trial met co-primary endpoints |
| 06/06/22 | 07:00:09 | 6 Jun 2022 | | Enhertu efficacy results in HER2-low breast cancer |
| 01/06/22 | 15:00:00 | 1 Jun 2022 | | Block listing Interim Review |
| 01/06/22 | 15:00:00 | 1 Jun 2022 | | Total Voting Rights |
| 20/05/22 | 16:00:04 | 20 May 2022 | | Director/PDMR Shareholding |
| 09/05/22 | 13:00:01 | 9 May 2022 | | Appointment of joint corporate brokers |
| 06/05/22 | 16:00:01 | 6 May 2022 | | Director/PDMR Shareholding |
| 05/05/22 | 07:10:02 | 5 May 2022 | | Enhertu approved in US for 2L HER2+ breast cancer |
| 05/05/22 | 07:05:01 | 5 May 2022 | | Farxiga HFpEF Phase III trial met primary endpoint |
| 05/05/22 | 07:00:04 | 5 May 2022 | | Ultomiris NMOSD Ph. III trial met primary endpoint |
| 04/05/22 | 07:00:04 | 4 May 2022 | | Imfinzi combo granted Priority Review for BTC |
| 03/05/22 | 15:00:02 | 3 May 2022 | | Total Voting Rights |
| 29/04/22 | 17:30:04 | 29 Apr 2022 | | Result of AGM |
| 29/04/22 | 07:05:01 | 29 Apr 2022 | | AstraZeneca plans new R&D centre in Massachusetts |
| 29/04/22 | 07:00:03 | 29 Apr 2022 | | First quarter 2022 results |
| 28/04/22 | 07:00:12 | 28 Apr 2022 | | Ultomiris approved in the US for adults with gMG |
| 27/04/22 | 07:00:11 | 27 Apr 2022 | | Enhertu granted BTD for HER2-low breast cancer |
| 25/04/22 | 07:00:08 | 25 Apr 2022 | | Tremelimumab US Priority Review for Imfinzi combo |
| 19/04/22 | 07:00:11 | 19 Apr 2022 | | Enhertu granted Priority Review for HER2m NSCLC |
| 01/04/22 | 15:00:05 | 1 Apr 2022 | | Total Voting Rights |
| 29/03/22 | 07:00:09 | 29 Mar 2022 | | Ondexxya approved in Japan for FXai reversal |
| 28/03/22 | 07:00:09 | 28 Mar 2022 | | Evusheld approved in the EU for COVID-19 |
| 25/03/22 | 15:30:06 | 25 Mar 2022 | | Director/PDMR Shareholding |
| 24/03/22 | 18:00:06 | 24 Mar 2022 | | Evusheld Positive EU CHMP Opinion |
| 24/03/22 | 07:00:10 | 24 Mar 2022 | | Update on CALLA Phase III trial for Imfinzi |
| 23/03/22 | 11:00:02 | 23 Mar 2022 | | Notice of AGM |
| 17/03/22 | 07:00:05 | 17 Mar 2022 | | Settlement of patent litigation for Ultomiris |
| 14/03/22 | 07:05:07 | 14 Mar 2022 | | Lynparza approved in US for early breast cancer |
